


Current real-life management of aplastic anemia in the elderly in France



Therapeutic options for AA

- Anti-thymocyte globulin (ATG) + cyclosporine-A (CsA)
- CsA alone

ATG-CsA regimen is recommended as first-line in patients over the age of 60 with severe or very severe AA



Retrospective nationwide multicenter study in 19 centers in France



88

Patients with aplastic anemia (AA), median age of 68.5 years (range 60-89)

- Mild AA (43%)
- Severe AA (36%)
- Very severe (21%)



184

Treatment lines (median of 2 lines per patient (range 1-5))

33% ATG-CsA	14% Androgen alone	9% CsA + androgen or eltrombopag
14% CsA alone	10% Eltrombopag alone	1% Allo-HSCT
		19% Others



Median time of follow-up

32.1 months

After first-line therapy

32% complete response
15% partial response
70% overall response rate

- Age
- Charlson comorbidity index
- Very severe aplastic anemia

independently associated with mortality

Three-year survival

74.7% (median 7.36 years)

Age per se is not a limiting factor to AA treatment with ATG-CsA; this regimen should be used as a first-line treatment in elderly patients if they have a good performance status and low comorbidity index score